Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option
★★★★★ monitor_heart Health Score: 78/100 · GoodICICI Prudential Mutual Fund · Equity · Sectoral/ Thematic
₹42.91
AUM: ₹6,668 Cr
NAV updated 19 days ago
Plan
—
Option
—
Risk
Very High
Expense Ratio
1.4%
Exit Load
Exit load of 1% if redeemed within 15 days.
Fund Manager
Ihab Dalwai, Priyanka Khandelwal
Inception
Jul 2018
Benchmark
BSE Healthcare Total Return Index
Sharpe Ratio
0.06
Std Dev (1Y)
13.91%
Historical Returns (CAGR)
Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.
1m
+6.42%
3m
+18.77%
6m
+8.22%
1y
+8.74%
3y
+25.42%
5y
+16.06%
10y
—
since inception
+20.43%
rate_review TopFund's Take on ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option holds up reasonably well within the Sectoral/ Thematic category, backed by a 4-star rating. Consistent 3-year performance combined with a strong rating makes this one of the more credible options in its space. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 78/100.
Cost: At 1.4%, the expense ratio runs 31% above the Sectoral/ Thematic category average of 1.07%. That gap is worth weighing against the fund's actual performance versus cheaper peers before committing to a long SIP.
Risk-adjusted performance: Over the trailing 1-year period, the fund shows a modest Sharpe ratio of 0.06 — returns have only marginally compensated for the risk taken. Separately, annualised volatility of 13.91% is fairly typical for actively managed equity funds.
Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.
This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.
donut_small Sector Allocation
pie_chart Asset Allocation
info Fund Snapshot
Similar Funds
Invesco India Financial Services Fund - Direct Plan - Growth
Invesco Mutual Fund
Franklin India Opportunities Fund - Direct - Growth
Franklin Templeton Mutual Fund
ICICI Prudential Manufacturing Fund - Direct Plan - Cumulative Option
ICICI Prudential Mutual Fund
TATA India Consumer Fund Direct Plan - Reinvestment of Income Distribution cum capital withdrawal option
Tata Mutual Fund
DSP India T.I.G.E.R. Fund - Direct Plan - Growth
DSP Mutual Fund
Invesco India PSU Equity Fund - Direct Plan - Growth
Invesco Mutual Fund
tips_and_updates Tools & Guides for This Fund
Frequently Asked Questions about ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option
The current NAV (Net Asset Value) of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option is ₹42.91. NAV is updated every business day after market close by AMFI.
1Y: 8.74% · 3Y CAGR: 25.42% · 5Y CAGR: 16.06%
The expense ratio is 1.4% per annum — the annual fee deducted from your investment to cover fund management costs.
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option is managed by Ihab Dalwai, Priyanka Khandelwal at ICICI Prudential Mutual Fund.
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option is a Very High risk fund. Suitable for aggressive investors with a 5+ year horizon.
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option is a Sectoral/ Thematic fund. SIP suitability depends on your investment goal and risk profile.
The Assets Under Management (AUM) of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option is ₹6,669 crore as of the latest data.
* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.